Nat Rev Gastroenterol Hepatol (2018) 34:274
Bulow Pedersen, I
Ro Body Program features a similar structure to Hims with compounded semaglutide, but pricing is higher and choices are narrower
Pharmaceutics 15:1246 Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M, Nagao S, Wainscott DB, Showalter AD, Droz BA, Kobilka TS, Coghlan MP, Willard FS, Kawabe Y, Kobilka BK, Sloop KW (2020) Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
No human-benefit claims The 5-Amino-1MQ studies cited on this page involve biochemical assays, cultured cells, analytical methods, or rodents
Other considerations include if this class of medications is dropped from coverage, patients on the drugs will need to find other ways to pay for it if they want to continue, the affordability and availability of the medications, and what will the long-term impact be if patients stop taking the medications suddenly